{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T08:54:47Z","timestamp":1776329687109,"version":"3.50.1"},"reference-count":11,"publisher":"Baskent University","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Clin Transplant"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.6002\/ect.2022.0046","type":"journal-article","created":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T03:19:11Z","timestamp":1653362351000},"page":"1122-1125","source":"Crossref","is-referenced-by-count":1,"title":["Coadministration of Immunosuppressant Treatments With Pegloticase in the Context of Solid-Organ Transplantation and Gout: A Case Report"],"prefix":"10.6002","volume":"20","author":[{"given":"Anna","family":"Kilzer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Klingemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ted R.","family":"Mikuls","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoffrey M.","family":"Thiele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison","family":"Petro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Feely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4021","reference":[{"key":"ref0","unstructured":"References"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"1. Sundy JS, Baraf HS, Yood RA, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011;306(7):711-720. doi:10.1001\/jama.2011.1169","DOI":"10.1001\/jama.2011.1169"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"2. Lipsky PE, Calabrese LH, Kavanaugh A, et al. Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout. Arthritis Res Ther. 2014;16(2):R60. doi:10.1186\/ar4497","DOI":"10.1186\/ar4497"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"3. Jani M, Barton A, Warren RB, Griffiths CE, Chinoy H. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology (Oxford). 2014;53(2):213-222. doi:10.1093\/rheumatology\/ket260","DOI":"10.1093\/rheumatology\/ket260"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1136\/annrheumdis-2019-eular.3475","article-title":"Pretreatment and co-administration with methotrexate improved durability of pegloticase response: a prospective, observational, proof-of-concept, case series","volume":"78","author":"Botson","year":"2019","unstructured":"4. Botson J, Peterson J. Pretreatment and co-administration with methotrexate improved durability of pegloticase response: a prospective, observational, proof-of-concept, case series. Ann Rheum Dis. 2019;78:1289-1290","journal-title":"Ann Rheum Dis"},{"key":"ref5","unstructured":"5. Albert J, Hosey T, LaMoreaux B. Subcutaneous or oral methotrexate exposure and response to pegloticase in uncontrolled gout patients in a community rheumatology practice [abstract]. Arthritis Rheumatol. 2019;71(suppl 10). https:\/\/acrabstracts.org\/abstract\/subcutaneous-or-oral-methotrexate-exposure-and-response-to-pegloticase-in-uncontrolled-gout-patients-in-a-community-rheumatology-practice\/"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"6. Berhanu AA, Krasnokutsky S, Keenan RT, Pillinger MH. Pegloticase failure and a possible solution: Immunosuppression to prevent intolerance and inefficacy in patients with gout. Semin Arthritis Rheum. 2017;46(6):754-758. doi:10.1016\/j.semarthrit.2016.09.007","DOI":"10.1016\/j.semarthrit.2016.09.007"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"7. Freyne B. A case report of immunosuppressant medication-associated polyarticular tophaceous gout successfully treated using the polyethylene glycol-conjugated uricase enzyme pegloticase. Transplant Proc. 2018;50(10):4099-4101. doi:10.1016\/j.transproceed.2018.03.010","DOI":"10.1016\/j.transproceed.2018.03.010"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"8. Hershfield MS, Ganson NJ, Kelly SJ, Scarlett EL, Jaggers DA, Sundy JS. Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients. Arthritis Res Ther. 2014;16(2):R63. doi:10.1186\/ar4500","DOI":"10.1186\/ar4500"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"9. Khanna PP, Khanna D, Cutter G, et al. Reducing immunogenicity of pegloticase with concomitant use of mycophenolate mofetil in patients with refractory gout: a phase II, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2021;73(8):1523-1532. doi:10.1002\/art.41731","DOI":"10.1002\/art.41731"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"10. Botson JK, Tesser JRP, Bennett R, et al. Pegloticase in combination with methotrexate in patients with uncontrolled gout: a multicenter, open-label study (MIRROR). J Rheumatol. 2021;48(5):767-774. doi:10.3899\/jrheum.200460","DOI":"10.3899\/jrheum.200460"}],"container-title":["Experimental and Clinical Transplantation"],"original-title":[],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T03:30:03Z","timestamp":1675135803000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.ectrx.org\/detail\/archive\/2022\/20\/12\/0\/1122\/0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":11,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"URL":"https:\/\/doi.org\/10.6002\/ect.2022.0046","relation":{},"ISSN":["1304-0855","2146-8427"],"issn-type":[{"value":"1304-0855","type":"print"},{"value":"2146-8427","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12]]}}}